Drug Trial Radar · NCT01329029
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
Last checked: Nov 19, 2026Latest source record: Dec 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,945
Actual
Start
May 2011
Primary completion
Mar 2014
Study completion May 2014
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 5, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects. Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
RoflumilastDrug
500 µg, once daily
PlaceboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate or Severe COPD Exacerbations Per Patient Per YearTime frame: 52 weeks
Locations
180 sites in 21 countries. Site status is shown where the registry gives one.
Nycomed Investigational Site
Box Hill, Australia
Nycomed Investigational Site
Clayton, Australia
Nycomed Investigational Site
Concord, Australia
Nycomed Investigational site
Daws Park, Australia
Nycomed Investigational Site
Frankston, Australia
Nycomed Investigational Site
Heidelberg, Australia
Nycomed Investigational Site
Parkville, Australia
Nycomed Investigational Site
Toorak Gardens, Australia
Nycomed Investigational Site
Feldbach, Austria
Nycomed Investigational Site
Graz, Austria
Nycomed Investigational Site
Salzburg, Austria
Nycomed Investigational Site
Vienna, Austria
Nycomed Investigational Site
Brussels, Belgium
Nycomed Investigational Site
Brussels, Belgium
Nycomed Investigational Site
Halen, Belgium
Nycomed Investigational Site
Liège, Belgium
Nycomed Investigational Site
Malmedy, Belgium
Nycomed Investigational Site
Belo Horizonte, Brazil
Nycomed Investigational Site
Botucatu, Brazil
Nycomed Investigational Site
Florianópolis, Brazil
Nycomed Investigational Site
Goiânia, Brazil
Nycomed Investigational Site
Porto Alegre, Brazil
Nycomed Investigational Site
Rio de Janeiro, Brazil
Nycomed Investigational Site
São Paulo, Brazil
Nycomed Investigational Site
Vitória, Brazil
Nycomed Investigational Site
Hamilton, Canada
Nycomed Investigational Site
Kingston, Canada
Nycomed Investigational Site
Lachine, Canada
Nycomed Investigational Site
Niagara Falls, Canada
Nycomed Investigational Site
Richmond Hill, Canada
Nycomed Investigational Site
Toronto, Canada
Nycomed Investigational Site
Toronto, Canada
Nycomed Investigational Site
Winnepeg, Canada
Nycomed Investigational Site
Hellerup, Denmark
Nycomed Investigational Site
Hillerød, Denmark
Nycomed Investigational Site
Hvidovre, Denmark
Nycomed Investigational Site
København NV, Denmark
Nycomed Investigational Site
Férolles-Attilly, France
Nycomed Investigational Site
Nîmes, France
Nycomed Investigational Site
Poitiers, France
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.